Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EMERGENT BIOSOLUTIONS INC.

(EBS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Insider Trends: Emergent BioSolutions Sees 90 Days of Insider Buying Trend Scaling Back with Share Sale

05/27/2021 | 04:43pm EDT


© MT Newswires 2021
All news about EMERGENT BIOSOLUTIONS INC.
10:42aASTRAZENECA : US authorities probing Emergent BioSolutions over COVID-19 vaccine..
RE
06:09aEMERGENT BIOSOLUTIONS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
07/29ASTRAZENECA : Emergent to resume J&J COVID-19 vaccine production at Baltimore pl..
RE
07/29EMERGENT BIOSOLUTIONS : Q2 Earnings Snapshot
AQ
07/29EMERGENT BIOSOLUTIONS : REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2021 (Form ..
PU
07/29EMERGENT BIOSOLUTIONS INC. : Results of Operations and Financial Condition, Regu..
AQ
07/29EMERGENT BIOSOLUTIONS : Earnings Flash (EBS) EMERGENT BIOSOLUTIONS Posts Q2 EPS ..
MT
07/29EMERGENT BIOSOLUTIONS : Earnings Flash (EBS) EMERGENT BIOSOLUTIONS Reports Q2 Re..
MT
07/29EMERGENT BIOSOLUTIONS : Reports Financial Results For Second Quarter 2021
AQ
07/29EMERGENT : FDA letting troubled COVID vaccine factory restart
AQ
More news
Financials (USD)
Sales 2021 1 785 M - -
Net income 2021 400 M - -
Net Debt 2021 152 M - -
P/E ratio 2021 8,78x
Yield 2021 -
Capitalization 3 495 M 3 495 M -
EV / Sales 2021 2,04x
EV / Sales 2022 2,06x
Nbr of Employees 2 200
Free-Float 88,6%
Chart EMERGENT BIOSOLUTIONS INC.
Duration : Period :
Emergent BioSolutions Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EMERGENT BIOSOLUTIONS INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 65,22 $
Average target price 86,00 $
Spread / Average Target 31,9%
EPS Revisions
Managers and Directors
Robert G. Kramer President, Chief Executive Officer & Director
Richard Scott Lindahl Chief Financial Officer, Treasurer & Executive VP
Fuad El Hibri Executive Chairman
Sharon M. Solomon Chief Information Officer & Senior Vice President
Karen L. Smith Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
EMERGENT BIOSOLUTIONS INC.-27.21%3 495
JOHNSON & JOHNSON9.40%453 418
ROCHE HOLDING AG12.49%335 069
PFIZER, INC.16.25%239 525
NOVARTIS AG-0.16%224 495
ELI LILLY AND COMPANY45.30%223 011